famotidine has been researched along with Lymph Node Metastasis in 4 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty patients with breast cancer were prospectively randomized into case and control groups receiving 40 mg famotidine preoperatively for 10-14 days and routine premedication, respectively." | 9.10 | Does famotidine enhance tumor infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study. ( Chattopadhyaya, TK; Gupta, SD; Kapoor, S; Kumar, A; Parshad, R, 2002) |
| "Famotidine may enhance the activity of T-cells further by allowing for increased IL-2 internalization by the IL-2 receptor on lymphocytes." | 5.36 | Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma. ( Knupp, C; Quan, F; Quan, W; Walker, P, 2010) |
| "Famotidine may increase IL-2 internalization by the IL-2 receptor on T-lymphocytes." | 5.35 | Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer. ( King, LA; Quan, FM; Quan, WD; Walker, PR, 2008) |
| "Thirty patients with breast cancer were prospectively randomized into case and control groups receiving 40 mg famotidine preoperatively for 10-14 days and routine premedication, respectively." | 5.10 | Does famotidine enhance tumor infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study. ( Chattopadhyaya, TK; Gupta, SD; Kapoor, S; Kumar, A; Parshad, R, 2002) |
| "Famotidine may enhance the activity of T-cells further by allowing for increased IL-2 internalization by the IL-2 receptor on lymphocytes." | 1.36 | Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma. ( Knupp, C; Quan, F; Quan, W; Walker, P, 2010) |
| "Famotidine may increase IL-2 internalization by the IL-2 receptor on T-lymphocytes." | 1.35 | Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer. ( King, LA; Quan, FM; Quan, WD; Walker, PR, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Quan, W | 2 |
| Knupp, C | 1 |
| Quan, F | 2 |
| Walker, P | 2 |
| Parshad, R | 1 |
| Kapoor, S | 1 |
| Gupta, SD | 1 |
| Kumar, A | 1 |
| Chattopadhyaya, TK | 1 |
| Ramirez, M | 1 |
| Taylor, C | 1 |
| Vinogradov, M | 1 |
| Quan, WD | 1 |
| Quan, FM | 1 |
| King, LA | 1 |
| Walker, PR | 1 |
2 trials available for famotidine and Lymph Node Metastasis
| Article | Year |
|---|---|
Does famotidine enhance tumor infiltrating lymphocytes in breast cancer? Results of a randomized prospective pilot study.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Breast Neoplasms; Carcinoma, Lobular; Case-Control Studies; F | 2002 |
Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over.
Topics: Adenosine; Aged; Aged, 80 and over; Aging; Capillary Leak Syndrome; Famotidine; Hemodynamics; Humans | 2005 |
2 other studies available for famotidine and Lymph Node Metastasis
| Article | Year |
|---|---|
Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cycl | 2010 |
Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Cycloph | 2008 |